Key Takeaway: Daré Bioscience has announced a strategic collaboration with MyMenopauseRx to enhance access to its DARE to PLAY™ menopause telehealth option. This partnership aims to expand Daré's commercial reach and strengthen consumer engagement within the women's health sector. The initiative is part of Daré's broader strategy to create a trusted ecosystem for women's health products and services.
Price reaction · baseline $1.32 (2026-07-27 close) · hit pre-market · clean, no other DARE news in the window
day 0 close
-10.2%
day 1 · peak
-12.1%
day 3
-7.6%
Market Sentiment Analysis
POSITIVE FACTORS
Expansion of access options for menopause care.
Collaboration enhances consumer engagement.
Advances Daré's strategy in women's health.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~5 mo
High dilution risk
Lead asset
Lopinavir/ ritonavir
Phase 2 · Human Papilloma Virus (HPV)
Full Press Release Details
A featured menopause telehealth option is now available to women exploring DARE to PLAY™, advancing Daré’s strategy to build a trusted women’s health ecosystem spanning products, education and access to care Collaboration will expand Daré’s commercial reach, strengthen consumer engagement and
Frequently Asked Questions
What is DARE to PLAY™?
DARE to PLAY™ is a menopause telehealth option offered by Daré Bioscience.
Who is collaborating with Daré Bioscience?
Daré Bioscience is collaborating with MyMenopauseRx.
What is the goal of the collaboration?
The collaboration aims to expand access to menopause care and strengthen consumer engagement.
How does this affect women's health options?
This partnership enhances the ecosystem of products and services available for women's health.